Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt


  • pmed.1003348

    Forlagets udgivne version, 1,4 MB, PDF-dokument

  • Signe Hässler
  • Delphine Bachelet
  • Julianne Duhaze
  • Natacha Szely
  • Aude Gleizes
  • Salima Hacein-Bey Abina
  • Orhan Aktas
  • Michael Auer
  • Jerôme Avouac
  • Mary Birchler
  • Yoram Bouhnik
  • Olivier Brocq
  • Dorothea Buck-Martin
  • Guillaume Cadiot
  • Franck Carbonnel
  • Yehuda Chowers
  • Manuel Comabella
  • Tobias Derfuss
  • Niek De Vries
  • Naoimh Donnellan
  • Abiba Doukani
  • Michael Guger
  • Hans-Peter Hartung
  • Eva Kubala Havrdova
  • Bernhard Hemmer
  • Tom Huizinga
  • Kathleen Ingenhoven
  • Poul Erik Hyldgaard-Jensen
  • Elizabeth C Jury
  • Michael Khalil
  • Bernd Kieseier
  • Anna Laurén
  • Raija Lindberg
  • Amy Loercher
  • Enrico Maggi
  • Jessica Manson
  • Claudia Mauri
  • Badreddine Mohand Oumoussa
  • Xavier Montalban
  • Maria Nachury
  • Petra Nytrova
  • Christophe Richez
  • Malin Ryner
  • Sellebjerg, Finn Thorup
  • Claudia Sievers
  • Dan Sikkema
  • Martin Soubrier
  • Sophie Tourdot
  • Caroline Trang
  • Alessandra Vultaggio
  • ABIRISK Consortium

BACKGROUND: Biopharmaceutical products (BPs) are widely used to treat autoimmune diseases, but immunogenicity limits their efficacy for an important proportion of patients. Our knowledge of patient-related factors influencing the occurrence of antidrug antibodies (ADAs) is still limited.

METHODS AND FINDINGS: The European consortium ABIRISK (Anti-Biopharmaceutical Immunization: prediction and analysis of clinical relevance to minimize the RISK) conducted a clinical and genomic multicohort prospective study of 560 patients with multiple sclerosis (MS, n = 147), rheumatoid arthritis (RA, n = 229), Crohn's disease (n = 148), or ulcerative colitis (n = 36) treated with 8 different biopharmaceuticals (etanercept, n = 84; infliximab, n = 101; adalimumab, n = 153; interferon [IFN]-beta-1a intramuscularly [IM], n = 38; IFN-beta-1a subcutaneously [SC], n = 68; IFN-beta-1b SC, n = 41; rituximab, n = 31; tocilizumab, n = 44) and followed during the first 12 months of therapy for time to ADA development. From the bioclinical data collected, we explored the relationships between patient-related factors and the occurrence of ADAs. Both baseline and time-dependent factors such as concomitant medications were analyzed using Cox proportional hazard regression models. Mean age and disease duration were 35.1 and 0.85 years, respectively, for MS; 54.2 and 3.17 years for RA; and 36.9 and 3.69 years for inflammatory bowel diseases (IBDs). In a multivariate Cox regression model including each of the clinical and genetic factors mentioned hereafter, among the clinical factors, immunosuppressants (adjusted hazard ratio [aHR] = 0.408 [95% confidence interval (CI) 0.253-0.657], p < 0.001) and antibiotics (aHR = 0.121 [0.0437-0.333], p < 0.0001) were independently negatively associated with time to ADA development, whereas infections during the study (aHR = 2.757 [1.616-4.704], p < 0.001) and tobacco smoking (aHR = 2.150 [1.319-3.503], p < 0.01) were positively associated. 351,824 Single-Nucleotide Polymorphisms (SNPs) and 38 imputed Human Leukocyte Antigen (HLA) alleles were analyzed through a genome-wide association study. We found that the HLA-DQA1*05 allele significantly increased the rate of immunogenicity (aHR = 3.9 [1.923-5.976], p < 0.0001 for the homozygotes). Among the 6 genetic variants selected at a 20% false discovery rate (FDR) threshold, the minor allele of rs10508884, which is situated in an intron of the CXCL12 gene, increased the rate of immunogenicity (aHR = 3.804 [2.139-6.764], p < 1 × 10-5 for patients homozygous for the minor allele) and was chosen for validation through a CXCL12 protein enzyme-linked immunosorbent assay (ELISA) on patient serum at baseline before therapy start. CXCL12 protein levels were higher for patients homozygous for the minor allele carrying higher ADA risk (mean: 2,693 pg/ml) than for the other genotypes (mean: 2,317 pg/ml; p = 0.014), and patients with CXCL12 levels above the median in serum were more prone to develop ADAs (aHR = 2.329 [1.106-4.90], p = 0.026). A limitation of the study is the lack of replication; therefore, other studies are required to confirm our findings.

CONCLUSION: In our study, we found that immunosuppressants and antibiotics were associated with decreased risk of ADA development, whereas tobacco smoking and infections during the study were associated with increased risk. We found that the HLA-DQA1*05 allele was associated with an increased rate of immunogenicity. Moreover, our results suggest a relationship between CXCL12 production and ADA development independent of the disease, which is consistent with its known function in affinity maturation of antibodies and plasma cell survival. Our findings may help physicians in the management of patients receiving biotherapies.

TidsskriftPLoS Medicine
Udgave nummer10
Antal sider27
StatusUdgivet - 2020

ID: 262761988